news 
Title: Blame The Game Or The Players? Regulating Pharmacy Benefit Managers
The heated debate surrounding pharmacy benefit managers (PBMs) has reached a boiling point. While it is easy to point fingers at these middlemen, we must not overlook the underlying system that enables their questionable practices. It’s time to blame the game rather than just the players.
Pharmacy benefit managers have been under intense scrutiny lately, with many questioning their role in the skyrocketing cost of prescription medications. And rightly so – as academics and experts, it is our responsibility to critically examine the industry’s dynamics.
Firstly, PBMs are not solely responsible for the rise in healthcare costs. Rather, we must acknowledge that the current system incentivizes these middlemen to prioritize profits over patient care. The safe harbor protections in Congress allow them to retain drug rebates, which ultimately results in higher list prices and, subsequently, increased patient cost sharing.
Moreover, insurance regulations impose an administrative burden on the system, making it challenging for patients to directly purchase generic drugs at a lower cost. This complexity enables PBMs to exploit the market, increasing spending and premiums while reducing pharmacy reimbursements.
These regulatory issues have created an environment where PBMs can thrive by engaging in practices like spread pricing – charging insurance companies more than they pay pharmacies. It’s a vicious cycle that not only harms patients but also undermines the credibility of the entire healthcare system.
Rather than solely blaming PBMs, we must reexamine the rules of the game that enable these behaviors. Strengthening regulations and adjusting incentives can help align the interests of all stakeholders – patients, providers, and payers alike.
In conclusion, it is essential to recognize that every player in the drug supply chain seeks to make a profit. However, it is our duty as policymakers and healthcare professionals to create a system where these incentives do not come at the expense of patient care and well-being.
Source: http://www.forbes.com
